Breast Cancer

In this video, Erica L. Mayer, MD, MPH, an assistant professor of medicine at Harvard Medical School and a director of clinical research at Dana-Farber Cancer Institute, discussed results from the ADAPT HER2 study presented at ASCO 2021.

In this video, Erica L. Mayer, MD, MPH, an assistant professor of medicine at Harvard Medical School and a director of clinical research at Dana-Farber Cancer Institute, discussed results from the phase 2b GeparNuevo trial presented at ASCO 2021.

A longer duration of extended hormone therapy provided no benefit for postmenopausal women with hormone receptor-positive breast cancer who had received 5 years of adjuvant endocrine therapy, according to randomized phase 3 study results.

Total annual costs associated with metastatic breast cancer in the U.S. could exceed $152 billion in 2030, according to a study published in JNCI Cancer Spectrum.

The addition of pembrolizumab to first-line chemotherapy extended OS for certain patients with metastatic triple-negative breast cancer, according to topline data released by the agent’s manufacturer.

The FDA approved pembrolizumab for treatment of patients with high-risk, early-stage triple-negative breast cancer.

Although 5-year survival rates have increased for multiple cancer types among adolescents and young adults, little or no improvement has been observed for some common malignancies in this population, according to findings published in Cancer.

Andre Nussenzweig, PhD, received the ninth annual Basser Global Prize.

Disruptions in breast cancer care during the COVID-19 pandemic may have a small long-term cumulative impact on breast cancer mortality in the U.S., according to study findings published in Journal of the National Cancer Institute.

Gavin Jones, MD, was raised to “be the change” he wished to see in the world.